生物学的製剤とバイオシミラーRA薬の世界市場レポート 2025年

生物学的製剤とバイオシミラーRA薬市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR7.3％で195億1,000万米ドルに成長します。予測期間の成長は、生物学的製剤開発の増加、市場競争、ヘルスケア政策、患者の嗜好、臨床研究開発に起因しています。予測期間における主な動向としては、バイオシミラー市場競争の激化、個別化医療と精密治療、ドラッグデリバリーシステムの進歩、安全性と有効性の重視、患者中心のヘルスケアなどが挙げられます。

高齢者人口の増加と関節リウマチ罹患率の上昇が、生物製剤およびバイオシミラーRA治療薬市場を牽引しています。高齢者人口は60歳以上で構成され、関節リウマチは免疫系が誤って健康な細胞を攻撃する自己免疫疾患であり、主に関節に影響を及ぼします。加齢により免疫力が低下するため、この疾患は高齢者に多くみられます。生物学的製剤およびバイオシミラーRA治療薬は、従来の薬剤と比較して関節リウマチの治療に特に有効です。例えば、スイスに本部を置く国連の保健専門機関である世界保健機関（WHO）は、2020年には全世界で60歳以上の高齢者が約10億人に達し、2030年には14億人、2050年には21億人に増加すると推定していると報告しています。さらに、米国の公衆衛生機関である疾病対策予防センター（CDC）は、2040年までに米国における成人の関節炎患者数は7,840万人に増加し、3,460万人が関節炎による活動制限を経験すると予測しています。このように、高齢者人口の増加と関節リウマチの症例増加の組み合わせが、生物学的製剤とバイオシミラーのRA治療薬市場を牽引しています。

予測されるヘルスケア支出の増加は、生物学的製剤およびバイオシミラーRA薬市場の拡大を促進する構えです。ヘルスケア支出は、健康状態の予防、治療、管理に関連する費用を含む、医療品やサービスに対する個人、政府、組織による総支出を包含します。生物学的製剤およびバイオシミラーRA治療薬は、専門的で高額になりがちな治療を費用対効果の高い方法で提供することにより、関節リウマチの管理を最適化する上で極めて重要な役割を果たしています。例えば、カナダを拠点とするInstitute for Health Information（CIHI）の予測によると、カナダの総医療費は2023年には3,440億米ドルに達し、カナダ人一人当たり8,740米ドルに達すると予想されています。これは、2022年の1.5％増に続き、2023年には2.8％増となります。ヘルスケア支出の増加は、生物学的製剤およびバイオシミラーRA市場にとって重要な促進要因です。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界生物学的製剤とバイオシミラーRA薬PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、制約）
• 最終用途産業の分析
• 世界の生物学的製剤とバイオシミラーRA薬市場：成長率分析
• 世界の生物学的製剤とバイオシミラーRA薬市場の実績：規模と成長, 2019-2024
• 世界の生物学的製剤とバイオシミラーRA薬市場の予測：規模と成長, 2024-2029, 2034F
• 世界生物学的製剤とバイオシミラーRA薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の生物学的製剤とバイオシミラーRA薬市場：ソース別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 微生物
• 哺乳類
• その他の情報源
• 世界の生物学的製剤とバイオシミラーRA薬市場：疾患別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 腫瘍学
• 免疫疾患
• 心血管疾患
• 血液疾患
• その他の病気
• 世界の生物学的製剤とバイオシミラーRA薬市場製造業別、実績と予測, 2019-2024, 2024-2029F, 2034F
• アウトソーシング
• 社内
• 世界の生物学的製剤とバイオシミラーRA薬市場購入方法別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 処方薬
• 市販薬（OTC）
• 世界の生物学的製剤とバイオシミラーRA薬市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• オンライン薬局
• 世界の生物学的製剤とバイオシミラーRA薬市場、微生物のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 細菌源
• 真菌源
• 酵母源
• 世界の生物学的製剤とバイオシミラーRA薬市場、哺乳類のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• チャイニーズハムスター卵巣（CHO）細胞
• ヒト胎児腎臓（HEK）細胞
• その他の哺乳類細胞株
• 世界の生物学的製剤とバイオシミラーRA薬市場、その他の情報源のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 植物由来の原料
• 昆虫由来の情報源
• 合成生物学のアプローチ

第7章 地域別・国別分析

• 世界の生物学的製剤とバイオシミラーRA薬市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の生物学的製剤とバイオシミラーRA薬市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 生物学的製剤とバイオシミラーRA薬市場：競合情勢
• 生物学的製剤とバイオシミラーRA薬市場：企業プロファイル
  • Samsung BioLogics Co. Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Novo Nordisk A/S Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Pfizer Inc.
• Merck & Co. Inc.
• Eli Lilly and Company
• Novartis AG
• Bayer AG
• F. Hoffmann-La Roche Ltd.
• AstraZeneca PLC
• Teva Pharmaceutical Industries Ltd.
• Fresenius Se & Co. KGaA
• Stada Arzneimittel AG
• Boehringer Ingelheim Pharmaceuticals Inc.
• Gedeon Richter Plc.
• La Roche Ltd.
• Regeneron Pharmaceuticals Inc.
• Bristol-Myers Squibb Company

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 生物学的製剤とバイオシミラーRA薬市場2029：新たな機会を提供する国
• 生物学的製剤とバイオシミラーRA薬市場2029：新たな機会を提供するセグメント
• 生物学的製剤とバイオシミラーRA薬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Biologics and biosimilars belong to a drug category derived from living organisms such as cells, microorganisms, and other living entities. Biosimilars are specifically designed to closely resemble an already approved biological drug. These medications are primarily used to treat rheumatoid arthritis (RA), a chronic inflammatory disorder.

The primary origins of RA drugs derived from biologics and biosimilars include microbial sources, involving bacteria, yeast, and fungi, along with mammalian and other sources. These medications are utilized to address a spectrum of diseases including oncology, immunological, cardiovascular, and hematological disorders. They are manufactured both through outsourced and in-house methods and are made available to patients through prescription and over-the-counter (OTC) channels, including hospital pharmacies, retail outlets, and online pharmacies.

The biologic & biosimilar RA drugs market research report is one of a series of new reports from The Business Research Company that provides biologic & biosimilar RA drugs market statistics, including biologic & biosimilar RA drugs industry global market size, regional shares, competitors with biologic & biosimilar RA drugs market share, detailed biologic & biosimilar RA drugs market segments, market trends, and opportunities, and any further data you may need to thrive in the biologic & biosimilar RA drugs industry. This biologic & biosimilar RA drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The biologic & biosimilar ra drugs market size has grown strongly in recent years. It will grow from $13.99 billion in 2024 to $14.71 billion in 2025 at a compound annual growth rate (CAGR) of 5.2%. The growth in the historic period can be attributed to market adoption rates, clinical trial outcomes, market share changes, long-term patient outcomes, pricing strategies.

The biologic & biosimilar ra drugs market size is expected to see strong growth in the next few years. It will grow to $19.51 billion in 2029 at a compound annual growth rate (CAGR) of 7.3%. The growth in the forecast period can be attributed to increasing biologic drug development, market competition, healthcare policies, patient preferences, clinical research & development. Major trends in the forecast period include rise in biosimilar market competition, personalized medicine and precision therapy, advancements in drug delivery systems, focus on safety and efficacy, patient-centric healthcare.

The growing older population and the rising incidence of rheumatoid arthritis are propelling the biologics and biosimilar RA drugs market. The older population consists of individuals aged 60 years and above, and rheumatoid arthritis is an autoimmune condition where the immune system mistakenly attacks healthy cells, primarily affecting the joints. This disease is more prevalent in older adults, as aging weakens the immune system. Biologics and biosimilar RA drugs are particularly effective in treating rheumatoid arthritis compared to conventional medications. For example, the World Health Organization (WHO), a specialized health agency of the United Nations based in Switzerland, reported that in 2020, there were approximately 1 billion people aged 60 and over globally, with projections estimating this number will rise to 1.4 billion by 2030 and 2.1 billion by 2050. Additionally, the Centers for Disease Control and Prevention (CDC), a US-based public health agency, anticipates that the number of adults with arthritis in the USA will increase to 78.4 million by 2040, with 34.6 million experiencing activity limitations due to arthritis. Thus, the combination of a growing geriatric population and increasing cases of rheumatoid arthritis is driving the biologics and biosimilars RA drugs market forward.

Anticipated growth in healthcare spending is poised to drive the expansion of the biologic and biosimilar RA drug market. Healthcare spending encompasses the total financial outlay by individuals, governments, and organizations on medical goods and services, encompassing expenses related to health condition prevention, treatment, and management. Biologic and biosimilar RA drugs play a pivotal role in optimizing the management of rheumatoid arthritis by providing specialized and often costly treatments in a cost-effective manner. For instance, projections by the Canada-based Institute for Health Information (CIHI) indicate that total health spending in Canada is expected to reach $344 billion in 2023, amounting to $8,740 per Canadian. This represents a 2.8% growth in 2023, following a 1.5% increase in 2022. The escalating healthcare spending landscape is a key driver for the biologic and biosimilar RA drug market.

A prominent trend contributing to popularity is the introduction of new innovations in the biologic and biosimilar RA drugs market. Major industry players are concentrating on the development of biosimilar treatments, exemplified by advancements such as Dual Concentration Biosimilar Options, offering cost-effective alternatives. Noteworthy is the collaboration between Organon, a US-based healthcare company, and Samsung Bioepis, a South Korea-based biopharmaceutical company. In July 2023, they launched HADLIMA, a biosimilar of Humira (adalimumab), in the US. HADLIMA, available in both high and low concentrations, aims to improve accessibility and affordability for patients with autoimmune diseases. Priced at an 85% discount to Humira, HADLIMA includes an autoinjector endorsed by the Arthritis Foundation and a patient support program called 'HADLIMA For You,' providing educational resources and co-pay support. Indicated for various conditions including rheumatoid arthritis and Crohn's disease, HADLIMA, with its dual concentration options, ensures seamless continuity of care for patients.

Leading companies in the biologic and biosimilar RA drugs market are securing approvals for groundbreaking biologics, including injectable medications, to enhance their offerings for the treatment of polymyalgia rheumatica. Injectable medications, typically administered in liquid form using a needle and syringe, are gaining prominence in expanding treatment options. For instance, in February 2023, Regeneron Pharmaceuticals, Inc., a US-based biotechnology company, and Sanofi, a France-based healthcare and pharmaceutical company, obtained FDA approval for Kevzara (sarilumab) to address polymyalgia rheumatica (PMR) in adults with an inadequate response to corticosteroids or those unable to tolerate corticosteroid taper. The approval stems from positive outcomes in the SAPHYR Phase 3 trial, where Kevzara demonstrated a significant 28% sustained remission rate compared to the placebo's 10% at 52 weeks. Originally approved for rheumatoid arthritis, Kevzara stands out as the first and only biologic treatment for PMR, providing relief from its debilitating symptoms.

In November 2022, Biocon, an India-based biopharmaceutical company, completed the acquisition of Viatris' global biosimilars business for $3 billion. This acquisition serves to bring patients, consumers, and payors closer to Biocon Biologics, offering direct commercial capabilities and supporting infrastructure across various emerging and advanced markets. Viatris, a US-based pharmaceutical company, specializes in manufacturing biosimilars for treating rheumatoid arthritis and other diseases. The acquisition positions Biocon Biologics to strengthen its presence and expand its reach in the biosimilars business, further solidifying its standing in the competitive landscape.

Major companies operating in the biologic & biosimilar RA drugs market include Samsung BioLogics Co. Ltd., Amgen Inc., Novo Nordisk A/S, AbbVie Inc., Johnson & Johnson Services Inc., Pfizer Inc., Merck & Co. Inc., Eli Lilly and Company, Novartis AG, Bayer AG, F. Hoffmann-La Roche Ltd., AstraZeneca PLC., Teva Pharmaceutical Industries Ltd., Fresenius Se & Co. KGaA, Stada Arzneimittel AG, Boehringer Ingelheim Pharmaceuticals Inc., Gedeon Richter Plc., La Roche Ltd., Regeneron Pharmaceuticals Inc., Bristol-Myers Squibb Company, Dr. Reddy's Laboratories Ltd., Biogen Inc., Genentech Inc., GlaxoSmithKline plc, Mylan N.V., Sandoz International GmbH, Amneal Pharmaceuticals LLC, Apotex Inc., Biocon Ltd., Coherus BioSciences Inc.

North America was the largest region in the biologic & biosimilar RA drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the biologic & biosimilar RA drugs market report during the forecast period. The regions covered in the biologic & biosimilar ra drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the biologic & biosimilar ra drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The biologics and biosimilars RA drugs market consists of sales of branded and generic biologics and biosimilar RA drugs. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Biologic & Biosimilar RA Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on biologic & biosimilar ra drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for biologic & biosimilar ra drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The biologic & biosimilar ra drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Source: Microbial; Mammalian; Other Sources
• 2) By Disease: Oncology; Immunological Disorders; Cardiovascular Disorders; Hematological Disorders; Other Diseases
• 3) By Manufacturing: Outsourced; In-House
• 4) By Mode Of Purchase: Prescription Drugs; Over-The-Counter (OTC) Drugs
• 5) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• Subsegments:
• 1) By Microbial: Bacterial Sources; Fungal Sources; Yeast Sources
• 2) By Mammalian: Chinese Hamster Ovary (CHO) Cells; Human Embryonic Kidney (HEK) Cells; Other Mammalian Cell Lines
• 3) By Other Sources: Plant-Based Sources; Insect-Based Sources; Synthetic Biology Approaches
• Companies Mentioned: Samsung BioLogics Co. Ltd.; Amgen Inc.; Novo Nordisk A/S; AbbVie Inc.; Johnson & Johnson Services Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Biologic & Biosimilar RA Drugs Market Characteristics

3. Biologic & Biosimilar RA Drugs Market Trends And Strategies

4. Biologic & Biosimilar RA Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Biologic & Biosimilar RA Drugs Growth Analysis And Strategic Analysis Framework

• 5.1. Global Biologic & Biosimilar RA Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Biologic & Biosimilar RA Drugs Market Growth Rate Analysis
• 5.4. Global Biologic & Biosimilar RA Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Biologic & Biosimilar RA Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Biologic & Biosimilar RA Drugs Total Addressable Market (TAM)

6. Biologic & Biosimilar RA Drugs Market Segmentation

• 6.1. Global Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Microbial
• Mammalian
• Other Sources
• 6.2. Global Biologic & Biosimilar RA Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oncology
• Immunological Disorders
• Cardiovascular Disorders
• Hematological Disorders
• Other Diseases
• 6.3. Global Biologic & Biosimilar RA Drugs Market, Segmentation By Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Outsourced
• In-House
• 6.4. Global Biologic & Biosimilar RA Drugs Market, Segmentation By Mode Of Purchase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Prescription Drugs
• Over-The-Counter (OTC) Drugs
• 6.5. Global Biologic & Biosimilar RA Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• 6.6. Global Biologic & Biosimilar RA Drugs Market, Sub-Segmentation Of Microbial, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Bacterial Sources
• Fungal Sources
• Yeast Sources
• 6.7. Global Biologic & Biosimilar RA Drugs Market, Sub-Segmentation Of Mammalian, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Chinese Hamster Ovary (CHO) Cells
• Human Embryonic Kidney (HEK) Cells
• Other Mammalian Cell Lines
• 6.8. Global Biologic & Biosimilar RA Drugs Market, Sub-Segmentation Of Other Sources, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Plant-Based Sources
• Insect-Based Sources
• Synthetic Biology Approaches

7. Biologic & Biosimilar RA Drugs Market Regional And Country Analysis

• 7.1. Global Biologic & Biosimilar RA Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Biologic & Biosimilar RA Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Biologic & Biosimilar RA Drugs Market

• 8.1. Asia-Pacific Biologic & Biosimilar RA Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Biologic & Biosimilar RA Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Biologic & Biosimilar RA Drugs Market, Segmentation By Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Biologic & Biosimilar RA Drugs Market

• 9.1. China Biologic & Biosimilar RA Drugs Market Overview
• 9.2. China Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Biologic & Biosimilar RA Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Biologic & Biosimilar RA Drugs Market, Segmentation By Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Biologic & Biosimilar RA Drugs Market

• 10.1. India Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Biologic & Biosimilar RA Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Biologic & Biosimilar RA Drugs Market, Segmentation By Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Biologic & Biosimilar RA Drugs Market

• 11.1. Japan Biologic & Biosimilar RA Drugs Market Overview
• 11.2. Japan Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Biologic & Biosimilar RA Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Biologic & Biosimilar RA Drugs Market, Segmentation By Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Biologic & Biosimilar RA Drugs Market

• 12.1. Australia Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Biologic & Biosimilar RA Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Biologic & Biosimilar RA Drugs Market, Segmentation By Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Biologic & Biosimilar RA Drugs Market

• 13.1. Indonesia Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Biologic & Biosimilar RA Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Biologic & Biosimilar RA Drugs Market, Segmentation By Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Biologic & Biosimilar RA Drugs Market

• 14.1. South Korea Biologic & Biosimilar RA Drugs Market Overview
• 14.2. South Korea Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Biologic & Biosimilar RA Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Biologic & Biosimilar RA Drugs Market, Segmentation By Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Biologic & Biosimilar RA Drugs Market

• 15.1. Western Europe Biologic & Biosimilar RA Drugs Market Overview
• 15.2. Western Europe Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Biologic & Biosimilar RA Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Biologic & Biosimilar RA Drugs Market, Segmentation By Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Biologic & Biosimilar RA Drugs Market

• 16.1. UK Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Biologic & Biosimilar RA Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Biologic & Biosimilar RA Drugs Market, Segmentation By Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Biologic & Biosimilar RA Drugs Market

• 17.1. Germany Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Biologic & Biosimilar RA Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Biologic & Biosimilar RA Drugs Market, Segmentation By Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Biologic & Biosimilar RA Drugs Market

• 18.1. France Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Biologic & Biosimilar RA Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Biologic & Biosimilar RA Drugs Market, Segmentation By Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Biologic & Biosimilar RA Drugs Market

• 19.1. Italy Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Biologic & Biosimilar RA Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Biologic & Biosimilar RA Drugs Market, Segmentation By Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Biologic & Biosimilar RA Drugs Market

• 20.1. Spain Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Biologic & Biosimilar RA Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Biologic & Biosimilar RA Drugs Market, Segmentation By Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Biologic & Biosimilar RA Drugs Market

• 21.1. Eastern Europe Biologic & Biosimilar RA Drugs Market Overview
• 21.2. Eastern Europe Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Biologic & Biosimilar RA Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Biologic & Biosimilar RA Drugs Market, Segmentation By Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Biologic & Biosimilar RA Drugs Market

• 22.1. Russia Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Biologic & Biosimilar RA Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Biologic & Biosimilar RA Drugs Market, Segmentation By Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Biologic & Biosimilar RA Drugs Market

• 23.1. North America Biologic & Biosimilar RA Drugs Market Overview
• 23.2. North America Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Biologic & Biosimilar RA Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Biologic & Biosimilar RA Drugs Market, Segmentation By Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Biologic & Biosimilar RA Drugs Market

• 24.1. USA Biologic & Biosimilar RA Drugs Market Overview
• 24.2. USA Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Biologic & Biosimilar RA Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Biologic & Biosimilar RA Drugs Market, Segmentation By Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Biologic & Biosimilar RA Drugs Market

• 25.1. Canada Biologic & Biosimilar RA Drugs Market Overview
• 25.2. Canada Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Biologic & Biosimilar RA Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Biologic & Biosimilar RA Drugs Market, Segmentation By Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Biologic & Biosimilar RA Drugs Market

• 26.1. South America Biologic & Biosimilar RA Drugs Market Overview
• 26.2. South America Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Biologic & Biosimilar RA Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Biologic & Biosimilar RA Drugs Market, Segmentation By Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Biologic & Biosimilar RA Drugs Market

• 27.1. Brazil Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Biologic & Biosimilar RA Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Biologic & Biosimilar RA Drugs Market, Segmentation By Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Biologic & Biosimilar RA Drugs Market

• 28.1. Middle East Biologic & Biosimilar RA Drugs Market Overview
• 28.2. Middle East Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Biologic & Biosimilar RA Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Biologic & Biosimilar RA Drugs Market, Segmentation By Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Biologic & Biosimilar RA Drugs Market

• 29.1. Africa Biologic & Biosimilar RA Drugs Market Overview
• 29.2. Africa Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Biologic & Biosimilar RA Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Biologic & Biosimilar RA Drugs Market, Segmentation By Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Biologic & Biosimilar RA Drugs Market Competitive Landscape And Company Profiles

• 30.1. Biologic & Biosimilar RA Drugs Market Competitive Landscape
• 30.2. Biologic & Biosimilar RA Drugs Market Company Profiles
  • 30.2.1. Samsung BioLogics Co. Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Novo Nordisk A/S Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Biologic & Biosimilar RA Drugs Market Other Major And Innovative Companies

• 31.1. Pfizer Inc.
• 31.2. Merck & Co. Inc.
• 31.3. Eli Lilly and Company
• 31.4. Novartis AG
• 31.5. Bayer AG
• 31.6. F. Hoffmann-La Roche Ltd.
• 31.7. AstraZeneca PLC
• 31.8. Teva Pharmaceutical Industries Ltd.
• 31.9. Fresenius Se & Co. KGaA
• 31.10. Stada Arzneimittel AG
• 31.11. Boehringer Ingelheim Pharmaceuticals Inc.
• 31.12. Gedeon Richter Plc.
• 31.13. La Roche Ltd.
• 31.14. Regeneron Pharmaceuticals Inc.
• 31.15. Bristol-Myers Squibb Company

32. Global Biologic & Biosimilar RA Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Biologic & Biosimilar RA Drugs Market

34. Recent Developments In The Biologic & Biosimilar RA Drugs Market

35. Biologic & Biosimilar RA Drugs Market High Potential Countries, Segments and Strategies

• 35.1 Biologic & Biosimilar RA Drugs Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Biologic & Biosimilar RA Drugs Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Biologic & Biosimilar RA Drugs Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer